Overexpression of IGF2BP2 has been found to confer shorter survival and poor prognosis in multiple cancers (39), including breast cancer (40), hepatocellular carcinoma (41), and pancreatic ductal adenocarcinoma (42, 43). This evidence concerns the gene IGF2BP2 and hepatocellular carcinoma.